A recent University College London research estimates that 1.6 million adults in England, Wales and Scotland used GLP-1s, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025, to lose weight.
doi: 10.1007/s11912-012-0244-x
Some weight-loss pen programs, such as Liraglutide, are designed for short-acting effects, requiring daily injections
For those in eligible plans, existing prior authorizations for weight loss drugs will no longer be valid after this date, and beneficiaries must revisit their provider to discuss coverage or alternative options
Key Takeaway: Combining Liposomal Vitamin C and Liposomal Glutathione maximizes the "redox cycle" in your body, ensuring that your antioxidant defenses are always recharged and ready to protect your cellular health
Furthermore, it has been shown to increase metabolism and activity, all of which cause weight loss (3)